Passage Bio, Inc. (PASG) Dividend History

Passage Bio, Inc. is a biopharmaceutical company focused on developing gene therapies for rare and devastating neurological and genetic disorders. Established with the goal of transforming patient lives, Passage Bio leverages its proprietary platform to discover and develop treatments targeting novel genetic and neurological conditions.

One Commerce Square, Philadelphia, PA, 19103
Phone: (267) 866-0312
Website: https://www.passagebio.com

Dividend History

Passage Bio, Inc. currently does not pay dividends

Company News

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

GlobeNewswire Inc.

Featured Companies: ADVM BIIB FDMT JNJ MGTX RARE RCKT RGNX SRPT TNYA
Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio, a clinical-stage genetic medicines company, announced that it will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference.

GlobeNewswire Inc.
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024. The company is focused on developing one-time therapies for neurodegenerative diseases, with its lead product candidate PBFT02 targeting frontotemporal dementia.

GlobeNewswire Inc.
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.

GlobeNewswire Inc.
Passage Bio Announces Positive Feedback from FDA on - GlobeNewswire

Passage Bio received positive feedback from the FDA to expand its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients, a move that could address a significant unmet need in this underserved patient community.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 18:35:52 UTC